Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ligand Pharmaceuticals (LGND) Capital Expenditures: 2010-2025

Historic Capital Expenditures for Ligand Pharmaceuticals (LGND) over the last 15 years, with Sep 2025 value amounting to $15,000.

  • Ligand Pharmaceuticals' Capital Expenditures was N/A to $15,000 in Q3 2025 from the same period last year, while for Sep 2025 it was -$72.7 million, marking a year-over-year change of. This contributed to the annual value of $1.8 million for FY2024, which is 48.28% down from last year.
  • Per Ligand Pharmaceuticals' latest filing, its Capital Expenditures stood at $15,000 for Q3 2025, which was down 92.99% from $214,000 recorded in Q2 2025.
  • In the past 5 years, Ligand Pharmaceuticals' Capital Expenditures registered a high of $74.9 million during Q2 2024, and its lowest value of -$73.2 million during Q4 2024.
  • Its 3-year average for Capital Expenditures is $578,500, with a median of $214,000 in 2025.
  • The largest annual percentage gain for Ligand Pharmaceuticals' Capital Expenditures in the last 5 years was 36,794.09% (2024), contrasted with its biggest fall of 17,648.92% (2024).
  • Over the past 5 years, Ligand Pharmaceuticals' Capital Expenditures (Quarterly) stood at $2.2 million in 2021, then decreased by 2.92% to $2.1 million in 2022, then plummeted by 80.43% to $417,000 in 2023, then slumped by 17,648.92% to -$73.2 million in 2024, then crashed by 99.71% to $15,000 in 2025.
  • Its Capital Expenditures stands at $15,000 for Q3 2025, versus $214,000 for Q2 2025 and $214,000 for Q1 2025.